References
- Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002–1006.
- Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462–469.
- Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large-B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
- Sehn LH, Berry B, Chhanabhai M, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
- Shizusawa T, Shibayama H, Murata S, et al. The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients. Leuk Lymphoma 2008;49:113–121.
- Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 1978;276:834–836.
- Tapia FJ, Polak JM, Barbosa AJ, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1981;1:808–811.
- Hirose T, Okuda K, Yamaoka T, et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung Cancer 2011;71:224–228.
- Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622–2628.
- Nakatsuka S, Nishiu M, Tomita Y, et al. Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL). Jpn J Cancer Res 2002;93:411–416.
- Fujiwara H, Arima N, Ohtsubo H, et al. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol 2002;71:80–84.
- Delsol G. [The 2008 WHO lymphoma classification]. Ann Pathol 2008;28 Spec No 1:S20–S24. [in French]
- Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994;22:261–268.
- Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004;130:107–113.
- Li JM, Wang L, Shen Y, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 2007;86:639–645.
- Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
- Hermans J, Krol AD, van Groningen K. International Prognostic Index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 1995;86:1460–1463.
- Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma 2011;52:46–52.
- Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985;52:257–263.
- Nemeth J, Galian A, Mikol J, Cochand-Priollet B, Wassef M, Lavergne A. Neuron-specific enolase and malignant lymphomas (23 cases). Virchows Arch A Pathol Anat Histopathol 1987;412:89–93.
- Massarelli G, Onida GA, Piras MA, et al. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin’s disease and large cell lymphomas. Anticancer Res 1999;19:3933–3938.
- Mohammad RM, Hamdan MY, Maki A, et al. Induced expression of α-enolase in differentiated diffuse large cell lymphoma. Enzyme Protein 1995;48:37–44.
- Moro MA, De Alba J, Cardenas A, et al. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose derivation in rat forebrain slices. Neuropharmacology 2000; 39:1309–1318.
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002;346:235–242.
- Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(Suppl. 2):2–9.